Payment overview · 2025
General Payments
$159.39
7 reported records · 5 companies
Healthcare provider profile · identity verified
Clari J Salgado Rios, MD
Allopathic & Osteopathic Physicians|General Practice · TAMPA, FL · NPI 1801052485
Verified facts
What the public records show
CMS Open Payments records show Clari J Salgado Rios, MD received $159.39 in general payments during 2025 across 7 reported records.
Novo Nordisk Inc accounted for 44.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $70.76 | 44.4% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.90 | 16.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.64 | 16.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.98 | 12.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.11 | 10.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $159.39 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $70.76 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $55.82 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $26.90 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $25.64 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 56 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 35 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
56 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 455 | 246 |
| Losartan Potassium | Losartan Potassium | 252 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 230 | 118 |
| Lisinopril | Lisinopril | 208 | 115 |
| Metformin Hcl | Metformin Hcl | 182 | 95 |
| Gabapentin | Gabapentin | 178 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 175 | 94 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 130 | 73 |
| Omeprazole | Omeprazole | 127 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 107 | 61 |
| Baclofen | Baclofen | 102 | 47 |
| Tramadol Hcl | Tramadol Hcl | 102 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 97 | 53 |
| Alprazolam | Alprazolam | 93 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 56 |
| Azithromycin | Azithromycin | 84 | 77 |
| Prednisone | Prednisone | 82 | 62 |
| Meloxicam | Meloxicam | 81 | 46 |
| Montelukast Sodium | Montelukast Sodium | 75 | 41 |
| Ibuprofen | Ibuprofen | 74 | 29 |
| Methylprednisolone | Methylprednisolone | 71 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 37 |
| Famotidine | Famotidine | 69 | 37 |
| Furosemide | Furosemide | 67 | 35 |
| Carvedilol | Carvedilol | 58 | 30 |
| Dexamethasone | Dexamethasone | 58 | 53 |
| Trazodone Hcl | Trazodone Hcl | 57 | 33 |
| Eliquis | Apixaban | 56 | 27 |
| Metformin Hcl Er | Metformin Hcl | 53 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 15 |
| Alendronate Sodium | Alendronate Sodium | 52 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 45 |
| Clonazepam | Clonazepam | 50 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 30 |
| Glimepiride | Glimepiride | 49 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 32 |
| Glipizide | Glipizide | 43 | 19 |
| Potassium Chloride | Potassium Chloride | 40 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 24 |
| Ozempic | Semaglutide | 37 | 15 |
| Sertraline Hcl | Sertraline Hcl | 36 | 20 |
| Simvastatin | Simvastatin | 36 | 19 |
| Jardiance | Empagliflozin | 35 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | 20 |
| Nifedipine Er | Nifedipine | 34 | 18 |
| Finasteride | Finasteride | 33 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 29 |
| Temazepam | Temazepam | 33 | 12 |
| Meclizine Hcl | Meclizine Hcl | 30 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | 17 |
| Ezetimibe | Ezetimibe | 27 | 19 |
| Glipizide Er | Glipizide | 26 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | 12 |
| Ammonium Lactate | Ammonium Lactate | 25 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 23 |
| Celecoxib | Celecoxib | 25 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | 14 |
| Buspirone Hcl | Buspirone Hcl | 23 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | 15 |
| Donepezil Hcl | Donepezil Hcl | 23 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | 15 |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 21 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 12 |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | 11 |
| Nystatin | Nystatin | 20 | 14 |
| Atenolol | Atenolol | 19 | 13 |
| Lorazepam | Lorazepam | 19 | suppressed |
| Allopurinol | Allopurinol | 18 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | 13 |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 15 |
| Benzonatate | Benzonatate | 15 | 13 |
| Pregabalin | Pregabalin | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 12 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $159.39 · 7 records | Novo Nordisk Inc | ELIQUIS, General - Pain Management, JARDIANCE, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error